Sophie Dalac-Rat

Valence, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 18 publications

Impact of the COVID-19 pandemic on melanoma: A retrospective study from the French clinical database of melanoma patients (RIC-Mel).

Impact of the COVID-19 pandemic on melanoma: A retrospective study from the French clinical database of melanoma patients (RIC-Mel).

Journal: Annales de dermatologie et de venereologie

Published: February 22, 2024

A phase 2 open-label study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (EMPOWER-CSCC-1): Final long-term analysis of groups 1, 2, and 3, and primary analysis of fixed-dose treatment group 6.

A phase 2 open-label study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (EMPOWER-CSCC-1): Final long-term analysis of groups 1, 2, and 3, and primary analysis of fixed-dose treatment group 6.

Journal: Journal of the American Academy of Dermatology

Published: January 05, 2024

Response to the letter: Hyperprogression in advanced melanoma is not restricted to immunotherapy.

Response to the letter: Hyperprogression in advanced melanoma is not restricted to immunotherapy.

Journal: European journal of cancer (Oxford, England : 1990)

Published: December 04, 2023

Differential gradients of immunotherapy vs targeted therapy efficacy according to the sun-exposure pattern of the site of occurrence of primary melanoma: a multicenter prospective cohort study (MelBase).

Differential gradients of immunotherapy vs targeted therapy efficacy according to the sun-exposure pattern of the site of occurrence of primary melanoma: a multicenter prospective cohort study (MelBase).

Journal: Frontiers in oncology

Published: June 29, 2023

Hyperprogression in advanced melanoma is not restricted to immunotherapy.

Hyperprogression in advanced melanoma is not restricted to immunotherapy.

Journal: European journal of cancer (Oxford, England : 1990)

Published: April 16, 2023

Duration of treatment with cemiplimab in advanced cutaneous squamous cell carcinoma in complete response: Real-life study.

Duration of treatment with cemiplimab in advanced cutaneous squamous cell carcinoma in complete response: Real-life study.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV

Published: April 06, 2023

Epidemiology and characteristics of acral lentiginous melanoma compared to lentigo melanoma in France: a multicentric retrospective study from the French cohort RIC-Mel database

Epidemiology and characteristics of acral lentiginous melanoma compared to lentigo melanoma in France: a multicentric retrospective study from the French cohort RIC-Mel database

Journal: European journal of dermatology : EJD

Published: March 01, 2023

Effectiveness of mogamulizumab in patients with Mycosis Fungoides or Sézary syndrome: A multicentre, retrospective, real-world French study.

Effectiveness of mogamulizumab in patients with Mycosis Fungoides or Sézary syndrome: A multicentre, retrospective, real-world French study.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV

Published: November 20, 2022

Cutaneous vasculitis associated with mycosis fungoides.

Cutaneous vasculitis associated with mycosis fungoides.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV

Published: May 09, 2022

An open label, non-randomised, phase IIIb study of trametinib in combination with dabrafenib in patients with unresectable (stage III) or distant metastatic (stage IV) BRAF V600-mutant melanoma: A subgroup analysis of patients with brain metastases.

An open label, non-randomised, phase IIIb study of trametinib in combination with dabrafenib in patients with unresectable (stage III) or distant metastatic (stage IV) BRAF V600-mutant melanoma: A subgroup analysis of patients with brain metastases.

Journal: European journal of cancer (Oxford, England : 1990)

Published: May 05, 2022

Efficacy, safety and factors associated with disease progression in patients with unresectable (stage III) or distant metastatic (stage IV) BRAF V600-mutant melanoma: An open label, non-randomized, phase IIIb study of trametinib in combination with dabrafenib.

Efficacy, safety and factors associated with disease progression in patients with unresectable (stage III) or distant metastatic (stage IV) BRAF V600-mutant melanoma: An open label, non-randomized, phase IIIb study of trametinib in combination with dabrafenib.

Journal: European journal of cancer (Oxford, England : 1990)

Published: March 05, 2021

Vismodegib in neoadjuvant treatment of locally advanced basal cell carcinoma: First results of a multicenter, open-label, phase 2 trial (VISMONEO study): Neoadjuvant Vismodegib in Locally Advanced Basal Cell Carcinoma.

Vismodegib in neoadjuvant treatment of locally advanced basal cell carcinoma: First results of a multicenter, open-label, phase 2 trial (VISMONEO study): Neoadjuvant Vismodegib in Locally Advanced Basal Cell Carcinoma.

Journal: EClinicalMedicine

Published: February 16, 2021

Showing 1-12 of 18

Last Updated: 09/26/2026